LNC Therapeutics
Microbiome | Develop | Innovate

Press release

LNC Therapeutics announces the deployment of a research platform focused exclusively on its gut microbiome activities

- **A dedicated team of research scientists studying the *Christensenella* genus bacteria and their role in the gut microbiome**

- **LNC Therapeutics' goal: extend the applications of its drug candidates based on *Christensenella* to new indications with substantial unmet medical needs**

Bordeaux, June 06th, 2019 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug research and development, announced today the deployment of a research platform focused exclusively on its gut microbiome activities and more precisely on analysis of the therapeutic properties of christensenella.

This proprietary platform aims to hone LNC Therapeutics' expertise by deepening its knowledge of the mechanisms of action and interactions between christensenella bacteria and the host. LNC Therapeutics intends to discover new therapeutic applications and to extend its product pipeline.

The new unit reinforces LNC Therapeutics' regulatory affairs and clinical teams and is formed of top-level researchers specialized in microbiology, cellular biology and molecular biology. It is implanted at the *Plateforme Technologique d'Innovation Biomédicale* (PTIB) in Bordeaux. The PTIB is linked to the University of Bordeaux and the Xavier Arnozan hospital. It aims to enhance and capitalize on biotechnology- and health-related research.

Located at the heart of the university hospital campus, LNC Therapeutics' platform enables the company to build special ties to a diverse range of academic and clinical teams, forge close patient relationships and gain access to cutting-edge research technologies.

"*We are delighted to be setting up our own research activities and thereby strengthening LNC Therapeutics' scientific expertise in gut microbiome and in particular christensenella bacteria",* commented Sandrine Claus, LNC Therapeutics' Chief Scientific Officer. *"Thanks to this new unit, LNC Therapeutics is now in a position to leverage its unique expertise to discover new therapeutic applications of this group of bacteria."*

"*With the deployment of this new research platform, LNC Therapeutics is now perfectly equipped to pursue its strategy to become a leading player in gut microbiome-based therapies"*, summed up Georges Rawadi, Chief Executive Officer of LNC Therapeutics. *"We truly believe that christensenella bacteria hold great therapeutic potential and that they play an essential role in the balance of the gut microbiome. We look forward to accelerating our research in this area to develop new applications to*

human health. To this end, our aim is to launch solutions as quickly as possible for patients suffering with serious illnesses for which there are no treatments available today."

About LNC Therapeutics – www.lnc.bio

Founded in 2010, LNC Therapeutics is a French biotech company specialized in research & development of gut microbiome-based drugs. LNC Therapeutics' goal is to develop new drug candidates to treat obesity and other metabolic diseases (LNC Therapeutics historical indications) and to enlarge its expertise to other indications for which no treatment exist yet.

Backed by leading venture capital investors such as Seventure Partners and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs.

For more information: www.lnc.bio - Follow us on Twitter @LNCTherapeutics

Contacts:

NewCap – Medias relations

Nicolas Merigeau - Arthur Rouillé
nmerigeau@newcap.fr - arouille@newcap.fr
01 44 71 94 98 - 01 44 71 00 15

LNC Therapeutics – Corporate communication

Caroline Bernard
caroline.bernard@lnc.bio
05 57 60 05 58